There has been quite a bit of research on CBD in the past year, contributing to greater understanding of the compound. Many of these studies focus on options to medicate with CBD as an alternative to current medical protocols. This article contains some notes from specific studies, but there were some generally accepted conclusions gained in 2017.
CBD has been shown to be a potential therapy for:
- Psychotic Disorders
- Stroke Rehabilitation
- High Blood Pressure
- Liver Injury
Given that CBD does not have any psychoactive component, the potential for little or no side effects makes it an increasingly popular choice.
Fear and Anxiety
Two studies conducted in Sao Paulo, Brazil at the Federal University of Santa Catarina and the University of Sao Paulo showed significant effects on event associated fear and anxiety.
The first found that CBD disrupted consolidation of specific long-term fear memory in rats. This study has important implications for PTSD treatment. Long-term fear memory is associated with experiencing a traumatic event. When the same or similar stimuli from the trauma event is reintroduced, subjects became frozen in fear. In this study, when rats received a CDS dose immediately after a traumatic event, they spent less time frozen in fear when the fearful stimuli was reintroduced. The timing of the CBD dose was an important factor in the study results.
The second study found that a 300mg dosage of CBD was associated with a significant reduction in anxiety immediately following a public speaking event. Subjects where given varied doses of CBD and the study stressed the importance of careful dose choices.
These studies paint a compelling picture of the positive effects of CBD on Fear and Anxiety. There are many potential uses, the most compelling of which is the replacement of drugs with dangerous side effects in current treatment protocols.
The opioid crisis is dangerous and results in tens of thousands of deaths in America every year. Opioid drugs have a high misuse rate (21-29 percent of chronic pain patients) and overdose rates have been steadily increasing year over year recently.
A study conducted by researchers at the University of California and Kent State University found that 97% of subjects reported that they were able to reduce their opiate use when using cannabis, and that 81% of subjects reported cannabis as more effective in treating chronic pain than opiates. It is important to specify that this study was not specifically conducted on CBD. The remarkably low side effects during the study and overwhelming positive subjective reporting will surely contribute to more research in the area.
A study was recently funded at Albert Einstein College of Medicine and Montefiore Health System that will look directly into whether CBD reduces opioid use among adults with chronic pain.
Irritable Bowel Disease
A 2017 study through the National Institutes of Health sought to find the effects of CBD on Irritable Bowel Diseas, Crohn’s, and Colitis. The study found that manipulation of the endocannabinoid system with CBD can provide substantial relief from colitis.
What’s next in CBD research?
While the studies we metion are only a few of the many conducted recently, they serve to indicate the broad treatment use possibilities of CBD. Many of the study findings await peer review and replication, but there is significant momentum in the area of CBD research.
More research, medical trials, and studies are needed to fully understand the treatment possibilities that CBD presents. Researchers continue to build on past studies to create compelling evidence for CBD as an alternate treatment protocol for many medical conditions.
Everyone should consult their doctor regarding all medical treatment protocols, and we hope to see these studies result in further education of the medical community on CBD and its potential uses.
 Vowles KE, McEntee ML, Julnes PS, Frohe T, Ney JP, van der Goes DN. Rates of opioid misuse, abuse, and addiction in chronic pain: a systematic review and data synthesis. Pain. 2015;156(4):569-576. doi:10.1097/01.j.pain.0000460357.01998.f1.